Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual M...
December 03 2018 - 7:00AM
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a
clinical stage immuno-oncology company developing innovative
therapies for the treatment of cancer, today announced that new
clinical data from the ongoing intratumoral trial of its
CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the
American Society of Hematology 60th Annual Meeting, December 1-4,
in San Diego, California.
“These results build upon the clinical data
reported at the EORTC Cutaneous Lymphoma Task Force meeting in
September and provide further evidence that intratumoral TTI-621 is
well tolerated and biologically active in patients with cutaneous
T-cell lymphoma,” said Dr. Niclas Stiernholm, president and CEO of
Trillium Therapeutics. “The signs of anti-tumor activity in
non-injected lesions are particularly encouraging, as are the
translational data demonstrating recruitment of cells of both the
innate and adaptive immune systems. We believe that this is the
most compelling evidence of single-agent activity of any
CD47-targeting agent in the clinic, and we are continuing to
execute a focused development plan in T-cell lymphoma.”
Poster Presentation
1653:Intralesional Administration of the CD47 Antagonist
TTI-621 (SIRPaFc) Induces Responses in Both Injected and
Non-injected Lesions in Patients with Relapsed/Refractory Mycosis
Fungoides and Sézary Syndrome: Interim Results of a Multicenter
Phase I Trial Presenter: Christiane Querfeld,
M.D., Ph.D., City of Hope National Medical Center
This poster presentation provided a further
update on the safety and anti-tumor activity observed in the
ongoing open label Phase 1 study of local TTI-621 administration in
highly pretreated patients with relapsed or refractory mycosis
fungoides or Sézary syndrome. Intratumoral TTI-621 was well
tolerated in 27 treated patients, with no grade 3 or higher
toxicity observed. A rapid reduction in Composite Assessment of
Index Lesion Severity (CAILS) scores, which measure local lesion
responses, was observed in 91% (20/22) of patients with available
scores across all disease stages, with 41% (9/22) exhibiting a 50%
or greater decrease in CAILS scores. Similar CAILS-based changes
were seen in adjacent non-injected lesions, suggesting local
regional effects that were not confined to the site of injection.
Continuation monotherapy beyond the initial two week induction
period led to further reductions in CAILS scores in 3/4 evaluable
patients and evidence of systemic effects were observed in one
patient. In addition, emerging translational data demonstrate that
local TTI-621 administration leads to a rapid influx of macrophages
and CD8+ T cells.
The poster is available in the Events &
Presentations section of Trillium’s website.
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target CD47,
a “do not eat” signal that cancer cells frequently use to evade the
immune system. Trillium also has a proprietary fluorine-based
medicinal chemistry platform that is being used to develop novel
compounds directed at undisclosed immuno-oncology targets.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). With respect to the forward-looking statements
contained in this press release, Trillium has made numerous
assumptions regarding, among other things: the effectiveness and
timeliness of preclinical and clinical trials; and the
completeness, accuracy and usefulness of the data. While Trillium
considers these assumptions to be reasonable, these assumptions are
inherently subject to significant scientific, business, economic,
competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors that could
cause Trillium's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements
contained in this press release. A discussion of risks and
uncertainties facing Trillium appears in Trillium's Annual
Information Form for the year ended December 31, 2017 filed with
Canadian securities authorities and available at www.sedar.com and
on Form 40-F with the U.S. Securities Exchange Commission and
available at www.sec.gov, each as updated by Trillium's continuous
disclosure filings, which are available at www.sedar.com and at
www.sec.gov. All forward-looking statements herein are qualified in
their entirety by this cautionary statement, and Trillium disclaims
any obligation to revise or update any such forward-looking
statements or to publicly announce the result of any revisions to
any of the forward-looking statements contained herein to reflect
future results, events or developments, except as required by
law.
Contact:James ParsonsChief
Financial Officer Trillium Therapeutics Inc. 416-595-0627
x232james@trilliumtherapeutics.com
Investor Relations:Jason
WongBlueprint Life Science Group for Trillium Therapeutics
415-375-3340 x4jwong@bplifescience.com
Media Relations:Jessica
TieszenCanale Communications for Trillium Therapeutics
619-849-5385jessica@canalecomm.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2023 to Apr 2024